No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
FHTX Foghorn Therapeutics
- 5.045
- -0.165-3.17%
Trading Apr 25 11:31 ET
214.74MMarket Cap-2155P/E (TTM)
5.180High4.800Low14.39KVolume5.040Open5.210Pre Close71.50KTurnover0.07%Turnover RatioLossP/E (Static)42.57MShares9.97052wk High-2.78P/B107.69MFloat Cap2.70052wk Low--Dividend TTM21.35MShs Float28.265Historical High--Div YieldTTM7.29%Amplitude2.700Historical Low4.968Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Insiders Sold Foghorn Therapeutics At US$6.56, Meanwhile Stock Sits Near US$5.53
Even though Foghorn Therapeutics Inc. (NASDAQ:FHTX) has fallen by 31% over the past week , insiders who sold US$72k worth of stock over the past year have had less luck.
Express News | Foghorn Therapeutics Has Appointed Kristian Humer As Chief Financial Officer
Express News | Foghorn Therapeutics Strengthens Financial Leadership With Appointment of Kristian Humer as Chief Financial Officer
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush
Foghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic Alliances
Express News | HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Comments
Update! Watching
$Foghorn Therapeutics(FHTX.US$ Foghorn Therapeutics Inc. is set to share updates on its cancer research pipeline during a conference call and webcast on April 9, 2024, coinciding with the AACR Annual Meeting. The company will outline progress in its preclinical trials, including the development of promising new inhibitors and degraders, with the intention of engaging with investors about these advancements. These forward-looking statements, while offering insights into potential...
1
$Foghorn Therapeutics(FHTX.US$
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
2
1
Foghorn Therapeutics' revenue estimates downgraded by analysts, expected losses per share increased. The company's slower growth compared to industry peers could be a concern for shareholders.
Foghorn Therapeutics' low P/S ratio may be due to investor skepticism about sustained strong revenue. The company's forecasted growth, lower than the industry average, could be causing shareholder unease and potentially impeding a strong share price rise.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg